American Heart Association/American College Of Cardiology Joint Science Advisory: AHA/ACC Issue Advisory On Diabetes Drugs And Heart Risk
February 24th, 2010 admin
Topics:
The data are inconclusive on heart risks from a class of blood sugar-lowering drugs called thiazolidinediones (TZDs) such as pioglitazone (Actos) or rosiglitazone (Avandia), but the medications should be used with close monitoring from healthcare providers according to a joint science advisory from the American College of Cardiology and the American Heart Association…
Related Posts
A Cedars-Sinai Heart Institute cardiologist co-authored the joint science advisory issued by the American Heart Association and the American College of Cardiology that calls for close monitoring of patients taking certain blood sugar-lowering drugs. Sanjay Kaul, M.D. co-authored the advisory about drugs called thiazolidinediones (TZDs) such as pioglitazone...
Collectively, the American Association of Clinical Endocrinologists (AACE), the American Diabetes Association, and The Endocrine Society continue to carefully review the information on rosiglitazone available in the public domain and await further information from the Food and Drug Administration (FDA) following the completion of the Joint Meeting...
A new analysis of diabetes medications Avandia (rosiglitazone) and Actos (pioglitazone) revealed that the risk of heart attack and/or heart failure, or death were the same, approximately 4%. The study has been published in the latest issue of Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal. Takeda Pharmacuetical...
In contrast to previous reports, the risks of the composite endpoint of heart attack, heart failure, both, or death were the same about 4 percent for patients taking the diabetes drugs rosiglitazone or pioglitazone, according to a study published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes…
Read More →
The Endocrine Society, American Diabetes Association and American Association of Clinical Endocrinologists issue joint statement in response to an FDA panel’s recommendation to keep rosiglitazone (Avandia) on the market The U.S…
Read More →
To combat the growing diabetes epidemic, the American Diabetes Association is asking Americans — “What will you do to Stop Diabetes? Know your risk.” On March 23, the 22nd annual American Diabetes Association Alert Day(SM), the Association is encouraging people to join the Stop Diabetes movement by taking the Diabetes Risk Test (at...
The US Senate Finance Committee has released a report, which followed a two-year inquiry into the safety of the diabetes drug Avandia (rosiglitazone), and the possibility of an increased incidence of adverse cardiovascular events…
Read More →
The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular (CV) safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals...
The Endocrine Society released a statement supporting the American Diabetes Association’s (ADA) new clinical practice recommendations adding the use of the A1C blood test to the traditional tests that use blood sugar measurements in the diagnosis of diabetes and pre-diabetes…
Read More →
As the FDA (Food and Drug Administration) advisory panel prepares to meet next week to discuss the safety of Avandia (Rosiglitazone), an anti-diabetic insulin sensitizer drug, FDA scientists continue to question its safety. The endocrinologic and metabolic advisory committees meet this Wednesday. They will also vote on whether they think the drug...
Related Tweets from Twitter
Related News from Digg
Leave a comment
| Trackback
